PMID- 19430007
OWN - NLM
STAT- MEDLINE
DCOM- 20090609
LR  - 20200203
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 20 Suppl 1
DP  - 2009 May
TI  - How to optimise treatment compliance in metastatic renal cell carcinoma with 
      targeted agents.
PG  - i7-12
LID - 10.1093/annonc/mdp073 [doi]
AB  - BACKGROUND: Targeted agents are being used increasingly for the treatment of 
      metastatic renal cell carcinoma (mRCC). Targeted agents are associated with a 
      distinct pattern of adverse events (AEs) in mRCC, which should be managed 
      promptly to ensure that patients maintain tumour control without impacting 
      quality of life. DESIGN: This article discusses the importance of maintaining 
      patients on optimum doses of targeted therapy to maximise treatment benefit, and 
      reviews the safety profiles of targeted agents in mRCC. Strategies for managing 
      the AEs associated with targeted agents are presented. RESULTS: Higher exposure 
      to targeted agents is positively associated with increased probability of 
      achieving improved overall survival, underlining the importance of maintaining 
      patients on appropriate doses to derive clinical benefit. Patients' risk profiles 
      should be assessed before commencing targeted therapy and patients should be 
      educated about AEs to aid early identification and treatment and improve 
      compliance. Practical steps can be taken to minimise the impact of AEs and 
      maintain patients on targeted therapy. CONCLUSIONS: Targeted agents are 
      associated with predictable AE profiles in mRCC. Early detection of 
      treatment-related AEs and effective implementation of management strategies can 
      reduce patient discomfort, avoid the need for dose reductions and 
      discontinuations, improve patient compliance and support optimal clinical 
      outcomes.
FAU - Ravaud, A
AU  - Ravaud A
AD  - Department of Medical Oncology and Radiotherapy, Hopital Saint-Andre, University 
      Hospital, Bordeaux and Universite Bordeaux, 2 Victor Segalen, Bordeaux, France. 
      alain.ravaud@chu-bordeaux.fr
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
SB  - IM
MH  - Carcinoma, Renal Cell/*drug therapy/secondary
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy/methods
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/secondary
MH  - *Patient Compliance
EDAT- 2009/05/14 09:00
MHDA- 2009/06/10 09:00
CRDT- 2009/05/12 09:00
PHST- 2009/05/12 09:00 [entrez]
PHST- 2009/05/14 09:00 [pubmed]
PHST- 2009/06/10 09:00 [medline]
AID - S0923-7534(19)56998-8 [pii]
AID - 10.1093/annonc/mdp073 [doi]
PST - ppublish
SO  - Ann Oncol. 2009 May;20 Suppl 1:i7-12. doi: 10.1093/annonc/mdp073.